Wave Life Sciences (WVE) Common Equity (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of Common Equity data on file, last reported at $453.5 million in Q2 2026.

• Quarterly Common Equity rose 225.65% year-over-year to $453.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $453.5 million (up 225.65% YoY) and the FY2025 annual result came in at $518.4 million, up 147.41% from the prior year.
• Common Equity slipped to $453.5 million in Q2 2026, from $511.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $518.4 million in Q4 2025 to a low of -$51.7 million in Q2 2023.
• A 5-year average of $121.5 million and a median of $35.3 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity plunged 65398.11% — and 2025, when it soared 4105.35%.
• Tracing WVE's Common Equity over 5 years: stood at -$45.1 million in 2022, then jumped by 187.89% to $39.6 million in 2023, then surged by 428.68% to $209.5 million in 2024, then jumped by 147.41% to $518.4 million in 2025, then declined by 12.51% to $453.5 million in 2026.
• The last three Common Equity figures came in at $453.5 million (Q2 2026), $511.7 million (Q1 2026), and $518.4 million (Q4 2025), per Business Quant data.